Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation

Annals of Hematology

Volumn 92, Issue 6, 2013, Pages 845-846

  Carr, Ryan ^a   Cataland, Spero R ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; ECULIZUMAB; PREDNISONE;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; CASE REPORT; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY BIOPSY; LABORATORY TEST; LEG EDEMA; LETTER; MALAISE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETREATMENT; SKIN BRUISING; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL, HUMANIZED; CESAREAN SECTION; COMBINED MODALITY THERAPY; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATING AGENTS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY DISEASES; KIDNEY TUBULAR NECROSIS, ACUTE; PLASMA EXCHANGE; POSTOPERATIVE COMPLICATIONS; PREDNISONE; PREGNANCY; PUERPERAL DISORDERS; RECURRENCE; REMISSION INDUCTION; RENAL DIALYSIS; YOUNG ADULT;

EID: 84877733678     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1622-z     Document Type: Letter

References (11)

1. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361(17):1676-1687. doi: 10.1056/NEJMra0902814
2. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233-1243. doi: 10.1056/NEJMoa061648
3. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117(25):6786-6792. doi: 10.1182/blood-2011-02-333997
4. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26(4):613-619. doi: 10.1007/s00467-010-1708-6
5. Chatelet V, Lobbedez T, Fremeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 42(10):4353-4355. doi: 10.1016/j.transproceed.2010.09.125
6. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360(5):544-546. doi: 10.1056/NEJMc0809959
7. Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P (2011) Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 26(4):621-624. doi: 10.1007/s00467-010-1719-3
8. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4(8):1312-1316. doi: 10.2215/CJN.01090209
9. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360(5):542-544. doi: 10.1056/NEJMc0808527
10. Prescott HC, Wu HM, Cataland SR, Baiocchi RA (2010) Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol 85(12):976-977. doi: 10.1002/ajh.21862
11. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7(1):23-35. doi: 10.1038/nrneph.2010.155